ONLY JARDIANCE ® 2, 3
RRR IN CV DEATH * 2, 5
ONLY JARDIANCE ® 2, 3
In people with T2D, risk of CV death is 2 to 3 times higher # 4
#
Compared to those without T2D.
38 %
RRR IN CV DEATH * 2, 5
* In adult patients with T2D and established CV Disease( CAD, PAD, MI or stroke) on top of SOC, versus placebo on top of SOC. Absolute risk for placebo vs JARDIANCE ®: 5.9 % vs 3.7 %( p < 0.001). Secondary endpoints. Primary endpoint of 3P MACE was met, HR 0.86, p = 0.04. 5
HR = 0.62; 95 % CI: 0.49, 0.77; p < 0.001. 2, 5
Start JARDIANCE ® with metformin. No HbA1c requirement. # 1
STARTING DOSE 2 INCREASING DOSE 2 STARTING DOSE 6 INCREASING DOSE 6
10 mg |
|
|
|
25 mg |
5 mg + metformin |
|
12.5 mg + metformin |
For additional glycaemic control 2 |
5 mg / 500 mg |
5 mg / 1000 mg |
12.5 mg / 500 mg
12.5 mg / 1000 mg
For additional glycaemic control * 6
|
Authority Required( STREAMLINED)
30 days: |
16220 |
60 days: |
16164 |
Authority Required( STREAMLINED)
30 days: |
16158 |
60 days: |
16162 |
#
In adults with T2D & CV Disease, High Risk of a CV Event ‡ or Identifying as First Nations Australians. 1 ‡ Defined as ≥10 % estimated risk in the next 5 years: www. cvdcheck. org. au. * Please consult the JARDIAMET ® Product Information for guidance on dosage of metformin in patients with renal impairment. If no adequate strength of JARDIAMET ® is available, individual monocomponents should be used. 6 Tablets not actual size.
|
SCAN FOR
JARDIANCE ® Product Information
|
PBS Information: JARDIANCE ®: Authority Required( STREAMLINED). Type 2 Diabetes. Refer to PBS Schedule for full Authority Required Information. |
|
|
PBS Information: JARDIAMET ®: Authority Required( STREAMLINED). Type 2 Diabetes. Refer to PBS Schedule for full Authority Required Information.
WARNING: Life threatening lactic acidosis can occur due to accumulation of metformin. Risk factors include renal impairment, old age and the use of high doses of metformin above 2000 mg per day.
|
|
SCAN FOR
JARDIAMET ® Product Information
|
BEFORE PRESCRIBING, PLEASE REVIEW THE FULL PRODUCT INFORMATION AVAILABLE FROM WWW. BOEHRINGER-INGELHEIM. COM. AU / PI OR BY SCANNING THE QR CODE.
Use of this medicinal product in paediatric patients aged 10 to 17 years with type 2 diabetes mellitus is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www. tga. gov. au / reporting-problems
References: 1. Pharmaceutical Benefits Scheme. Available at: www. pbs. gov. au. Accessed April 2025. 2. JARDIANCE ® Product Information. 3. Therapeutic Goods Administration. Available at: www. tga. gov. au. Accessed April 2025. 4. Coles BC et al. Diabetes Obes Metab 2001; 23:218 – 227. 5. Zinman B et al. N Engl J Med 2015; 373:2117 – 28. 6. JARDIAMET ® Product Information.
Abbreviations: CAD, coronary artery disease; CV, cardiovascular; eCVD, established cardiovascular disease; HR, hazard ratio; MACE, major adverse cardiovascular events; MI, myocardial infarction; PAD, peripheral artery disease; RRR, relative risk reduction; SGLT2i, sodium-glucose cotransporter 2 inhibitor; SOC, standard of care; T2D, type 2 diabetes.
EMPA-REG OUTCOME study design: a randomised, double-blind, placebo-controlled CV outcome trial to assess the effect of once-daily JARDIANCE ®( 10 mg or 25 mg) versus placebo on CV events in adults( n = 7,020) with T2D and established CV disease( CAD, PAD, MI or stroke) on top of standard of care( including antihypertensives, lipid-lowering agents, anticoagulants and glucose-lowering therapies). 5
Boehringer Ingelheim Pty Limited, ABN 52 000 452 308. 78 Waterloo Road, North Ryde, NSW 2113, Australia. Copyright © 2025. PC-AU-104326. Prepared March 2025. BOEH0736 _ AusDoc.
NEW PBS LISTING 1